Market Intelligence, Clinical Progress, and High-Purity Reagents for Dermatological and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CDSN drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CDSN ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View CDSN Products |
| Gene Delivery | CDSN Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for cell-adhesion and desquamation assays. |
View CDSN Products |
| Benchmark Ab | Anti-CDSN Recombinant Antibody Recombinant positive control for assay validation and epitope competition. |
View CDSN Products |
| Validator | CDSN siRNA Set For knockdown verification in primary keratinocyte models. |
View CDSN Products |
| Related Target A | DSG1 (Desmoglein-1) Core desmosomal cadherin co-localized with CDSN; essential for epidermal cohesion integrity. |
View DSG1 Products |
| Related Target B | KLK7 (Kallikrein-7) The primary stratum corneum protease responsible for the physiological cleavage of CDSN. |
View KLK7 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Glycosylation-Dependent Epitope Masking | HEK293 human host expression ensures native-like post-translational modifications (PTMs). |
| Protease Cleavage Assay Mimicry | Recombinant CDSN features sequence-verified cleavage sites for physiological KLK7 degradation screening. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live CDSN R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Corneodesmosin (CDSN) is gaining significant traction in dermatology and immunology. CDSN plays a pivotal role in maintaining the structural integrity of the stratum corneum and regulating desquamation. Aberrant CDSN expression or degradation is directly linked to severe skin barrier defects, including psoriasis, atopic dermatitis, and peeling skin syndrome (PSS).
The race for CDSN therapeutics is intensifying, with major players shifting focus from traditional mAbs to topical biologics and targeted protease modulators. As first-generation therapies reach the clinic, the next wave of R&D is targeting the preservation of the skin barrier by preventing premature CDSN degradation or, conversely, facilitating desquamation in hyperkeratotic diseases.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | Dermatology-focused Biopharma | Psoriasis, Atopic Dermatitis | Epitope mapping & binding affinity (Need native glycosylated CDSN-Fc) |
| Topical siRNAs / Gene Therapy | RNAi Therapeutics Specialists | Peeling Skin Syndrome (PSS) | Target knockdown validation (Need sequence-verified siRNA & Lentivirus) |
| Protease Inhibitors (KLK7/CDSN Axis) | Small Molecule Innovators | Netherton Syndrome, Ichthyosis | In vitro cleavage assays (Need stable recombinant CDSN substrate) |